These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7541509)

  • 1. Analysis of selective binding epitopes for the kappa-opioid receptor antagonist nor-binaltorphimine.
    Hjorth SA; Thirstrup K; Grandy DK; Schwartz TW
    Mol Pharmacol; 1995 Jun; 47(6):1089-94. PubMed ID: 7541509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor.
    Hjorth SA; Thirstrup K; Schwartz TW
    Mol Pharmacol; 1996 Oct; 50(4):977-84. PubMed ID: 8863844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
    Metzger TG; Paterlini MG; Ferguson DM; Portoghese PS
    J Med Chem; 2001 Mar; 44(6):857-62. PubMed ID: 11300867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists.
    Larson DL; Jones RM; Hjorth SA; Schwartz TW; Portoghese PS
    J Med Chem; 2000 Apr; 43(8):1573-6. PubMed ID: 10780914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential binding domains of peptide and non-peptide ligands in the cloned rat kappa opioid receptor.
    Xue JC; Chen C; Zhu J; Kunapuli S; DeRiel JK; Yu L; Liu-Chen LY
    J Biol Chem; 1994 Dec; 269(48):30195-9. PubMed ID: 7982926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the amino acid residues in the sixth transmembrane domains accessible in the binding-site crevices of mu, delta, and kappa opioid receptors.
    Xu W; Li J; Chen C; Huang P; Weinstein H; Javitch JA; Shi L; de Riel JK; Liu-Chen LY
    Biochemistry; 2001 Jul; 40(27):8018-29. PubMed ID: 11434771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dynamic relationship between mu and kappa opioid receptors in body temperature regulation.
    Chen X; McClatchy DB; Geller EB; Tallarida RJ; Adler MW
    Life Sci; 2005 Dec; 78(4):329-33. PubMed ID: 16257420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The conserved cysteine 7.38 residue is differentially accessible in the binding-site crevices of the mu, delta, and kappa opioid receptors.
    Xu W; Chen C; Huang P; Li J; de Riel JK; Javitch JA; Liu-Chen LY
    Biochemistry; 2000 Nov; 39(45):13904-15. PubMed ID: 11076532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of human kappa/mu opioid receptor chimeras that retain high affinity for dynorphin A.
    DeHaven RN; Mansson E; Daubert JD; Cassel JA
    Curr Top Med Chem; 2005; 5(3):303-13. PubMed ID: 15857313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DAMGO recognizes four residues in the third extracellular loop to discriminate between mu- and kappa-opioid receptors.
    Seki T; Minami M; Nakagawa T; Ienaga Y; Morisada A; Satoh M
    Eur J Pharmacol; 1998 Jun; 350(2-3):301-10. PubMed ID: 9696421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective κ opioid antagonists nor-BNI, GNTI and JDTic have low affinities for non-opioid receptors and transporters.
    Munro TA; Huang XP; Inglese C; Perrone MG; Van't Veer A; Carroll FI; Béguin C; Carlezon WA; Colabufo NA; Cohen BM; Roth BL
    PLoS One; 2013; 8(8):e70701. PubMed ID: 23976952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
    Jones RM; Hjorth SA; Schwartz TW; Portoghese PS
    J Med Chem; 1998 Dec; 41(25):4911-4. PubMed ID: 9836606
    [No Abstract]   [Full Text] [Related]  

  • 13. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies.
    Zhang H; Shi YG; Woods JH; Watson SJ; Ko MC
    Eur J Pharmacol; 2007 Sep; 570(1-3):89-96. PubMed ID: 17601558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mu and kappa opioid receptor expression in the mediobasal hypothalamus and effectiveness of selective antagonists on prolactin release during lactation.
    Tavakoli-Nezhad M; Arbogast LA
    Neuroscience; 2010 Mar; 166(2):359-67. PubMed ID: 20045447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
    Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
    Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of antagonists selective for mu, delta and kappa opioid receptors on the reinforcing effects of heroin in rats.
    Negus SS; Henriksen SJ; Mattox A; Pasternak GW; Portoghese PS; Takemori AE; Weinger MB; Koob GF
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1245-52. PubMed ID: 8389859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of phenolic address groups in opioid kappa receptor selective antagonists.
    Thomas JB; Fix SE; Rothman RB; Mascarella SW; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 2004 Feb; 47(4):1070-3. PubMed ID: 14761209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays.
    Takemori AE; Ho BY; Naeseth JS; Portoghese PS
    J Pharmacol Exp Ther; 1988 Jul; 246(1):255-8. PubMed ID: 2839664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid antagonist activity of naltrexone-derived bivalent ligands: importance of a properly oriented molecular scaffold to guide "address" recognition at kappa opioid receptors.
    Bolognesi ML; Ojala WH; Gleason WB; Griffin JF; Farouz-Grant F; Larson DL; Takemori AE; Portoghese PS
    J Med Chem; 1996 Apr; 39(9):1816-22. PubMed ID: 8627605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A chimeric analysis of the opioid receptor domains critical for the binding selectivity of mu opioid ligands.
    Watson B; Meng F; Akil H
    Neurobiol Dis; 1996 Feb; 3(1):87-96. PubMed ID: 9173916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.